|
1
|
Fossati R, Confalonieri C, Torri V,
Ghislandi E, Penna A, Pistotti V, Tinazzi A and Liberati A:
Cytotoxic and hormonal treatment for metastatic breast cancer: A
systematic review of published randomized trials involving 31,510
women. J Clin Oncol. 16:3439–3460. 1998.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Morgan G, Ward R and Barton M: The
contribution of cytotoxic chemotherapy to 5-year survival in adult
malignancies. Clin Oncol (R Coll Radiol). 16:549–560.
2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chabner BA and Roberts TG Jr: Timeline:
Chemotherapy and the war on cancer. Nat Rev Cancer. 5:65–72.
2005.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Banner R: Benchmark 30-day mortality rate
needed. Clin Oncol (R Coll Radiol). 21:733–734. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
World Health Organization (WHO):
Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Accessed Sep 13, 2020.
|
|
6
|
Shankar A, Saini D, Roy S, Mosavi Jarrahi
A, Chakraborty A, Bharti SJ and Taghizadeh-Hesary F: Cancer care
delivery challenges amidst coronavirus disease-19 (COVID-19)
outbreak: Specific precautions for cancer patients and cancer care
providers to prevent spread. Asian Pac J Cancer Prev. 21:569–573.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lambertini M, Toss A, Passaro A,
Criscitiello C, Cremolini C, Cardone C, Loupakis F, Viscardi G,
Meattini I, Dieci MV, et al: Cancer care during the spread of
coronavirus disease 2019 (COVID-19) in Italy: Young oncologists'
perspective. ESMO Open. 5(e000759)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hanna TP, Evans GA and Booth CM: Cancer,
COVID-19 and the precautionary principle: Prioritizing treatment
during a global pandemic. Nat Rev Clin Oncol. 17:268–270.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hofheinz RD, Wenz F, Post S, Matzdorff A,
Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et
al: Chemoradiotherapy with capecitabine versus fluorouracil for
locally advanced rectal cancer: A randomised, multicentre,
non-inferiority, phase 3 trial. Lancet Oncol. 13:579–588.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Biagi JJ, Raphael MJ, Mackillop WJ, Kong
W, King WD and Booth CM: Association between time to initiation of
adjuvant chemotherapy and survival in colorectal cancer: A
systematic review and meta-analysis. JAMA. 305:2335–2342.
2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Raphael MJ, Biagi JJ, Kong W, Mates M,
Booth CM and Mackillop WJ: The relationship between time to
initiation of adjuvant chemotherapy and survival in breast cancer:
A systematic review and meta-analysis. Breast Cancer Res Treat.
160:17–28. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ohe Y, Yamamoto S, Suzuki K, Hojo F,
Kakinuma R, Matsumoto T, Ohmatsu H and Nishiwaki Y: Risk factors of
treatment-related death in chemotherapy and thoracic radiotherapy
for lung cancer. Eur J Cancer. 37:54–63. 2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Radford JA, Ryder WDJ, Dodwell D, Anderson
H and Thatcher N: Predicting septic complications of chemotherapy:
An analysis of 382 patients treated for small cell lung cancer
without dose reduction after major sepsis. Eur J Cancer. 29A:81–86.
1992.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stephens RJ, Girling DJ and Machin D:
Treatment-related deaths in small cell lung cancer trials: Can
patients at risk be identified? Medical research council lung
cancer working party. Lung Cancer. 11:259–274. 1994.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gómez H, Hidalgo M, Casanova L, Colomer R,
Pen DL, Otero J, Rodríguez W, Carracedo C, Cortés-Funes H and
Vallejos C: Risk factors for treatment-related death in elderly
patients with aggressive non-Hodgkin's lymphoma: Results of a
multivariate analysis. J Clin Oncol. 16:2065–2069. 1998.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gilbar PJ, McPherson I, Aisthorpe GG and
Kondalsamy-Chennakes S: Systemic anticancer therapy in the last 30
days of life: Retrospective audit from an Australian regional
cancer centre. J Oncol Pharm Pract. 25:599–606. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Khoja L, McGurk A, O'Hara C, Chow S and
Hasan J: Mortality within 30 days following systemic anti-cancer
therapy, a review of all cases over a 4 year period in a tertiary
cancer centre. Eur J Cancer. 51:233–240. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ang E and Newton LV: Thirty-day mortality
after systemic anticancer treatment as a real-world,
quality-of-care indicator: The Northland experience. Intern Med J.
48:403–408. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pulgar B D, Yáñez B N and Ortega G F:
Mortality within 30 days of receiving systemic chemotherapy at a
regional oncology unit. Rev Med Chil. 147:887–890. 2019.PubMed/NCBI View Article : Google Scholar : (In Spanish).
|
|
20
|
Wallington M, Saxon EB, Bomb M, Smittenaar
R, Wickenden M, McPhail S, Rashbass J, Chao D, Dewar J, Talbot D,
et al: 30-day mortality after systemic anticancer treatment for
breast and lung cancer in England: A population-based,
observational study. Lancet Oncol. 17:1203–1216. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
O'Brien MER, Borthwick A, Rigg A, Leary A,
Assersohn L, Last K, Tan S, Milan S, Tait D and Smith IE: Mortality
within 30 days of chemotherapy: A clinical governance benchmarking
issue for oncology patients. Br J Cancer. 95:1632–1636.
2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Garassino MC, Whisenant JG, Huang LC,
Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini
AC, et al: COVID-19 in patients with thoracic malignancies
(TERAVOLT): First results of an international, registry-based,
cohort study. Lancet Oncol. 21:914–922. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kuderer NM, Choueiri TK, Shah DP, Shyr Y,
Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G
Jr, et al: Clinical impact of COVID-19 on patients with cancer
(CCC19): A cohort study. Lancet. 395:1907–1918. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He
JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical characteristics
of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720.
2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mehta V, Goel S, Kabarriti R, Cole D,
Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S,
Sparano JA, et al: Case fatality rate of cancer patients with
COVID-19 in a New York hospital system. Cancer Discov. 10:935–941.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nitulescu GM, Paunescu H, Moschos SA,
Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK,
Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to
treat SARS-CoV-2 infection: Mechanistic insights into current
COVID-19 therapies (Review). Int J Mol Med. 46:467–488.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
El Bairi K, Trapani D, Petrillo A, Le Page
C, Zbakh H, Daniele B, Belbaraka R, Curigliano G and Afqir S:
Repurposing anticancer drugs for the management of COVID-19. Eur J
Cancer. 141:40–61. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Curigliano G, Banerjee S, Cervantes A,
Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F,
Machiels JP, et al: Managing cancer patients during the COVID-19
pandemic: An ESMO multidisciplinary expert consensus. Ann Oncol.
31:1320–1335. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Al-Shamsi HO, Alhazzani W, Alhuraiji A,
Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK,
Hotte SJ, et al: A practical approach to the management of cancer
patients during the novel coronavirus disease 2019 (COVID -19)
pandemic: An international collaborative group. Oncologist.
25:e936–e945. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Saudi Arabia National Cancer Institute
(SANCI) Saudi National Cancer Institute Coronavirus Disease 2019
(COVID-19) Caregiver and Facility Clinical Practice Guidelines.
https://shc.gov.sa/Arabic/NCC/Documents/SaudiNationalCancerInstituteCOVID.pdf.
Accessed Jan 2, 2021.
|
